Taide Pharmaceutical (Zhejiang) Co., Ltd agreed to acquire Prometheus Biological Technology Co., Ltd from Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) for CNY 31.7 million on June 13, 2020. The company intends to sign an agreement. The parties to the agreement agree and confirm that the Taide pays the Guizhou in two phases in the following manner. In the first period, within fifteen working days after the entry into force of the agreement, Taide pays a 51% of the equity transfer price and the second period is within one year after the completion of the equity transfer, Taide will pay Guizhou the remaining 49% of the equity transfer price. For the period ending December 31, 20219, Prometheus reported total assets of CNY 240.28 million, Total owner's equity of CNY 221.92 million, Operating revenue of CNY 50.3 million, operating loss of CNY 0.76 million, Net loss of CNY 2.25 million. The transaction has been approved by Board of directors of Guizhou. Taide Pharmaceutical (Zhejiang) Co., Ltd completed the acquisition of Prometheus Bio Inc. from Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) on July 13, 2020. The industrial and commercial registration of equity transfer was completed on July 13, 2020. The transaction was approved by the shareholders of Guizhou Xinbang Pharmaceutical Co., Ltd. in the second extraordinary general meeting in 2020.